# PHA-739358 for the Treatment of Multiple Myeloma

> **NCT00872300** · PHASE2 · TERMINATED · sponsor: **Nerviano Medical Sciences** · enrollment: 7 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** PHA-739358

## Key facts

- **NCT ID:** NCT00872300
- **Lead sponsor:** Nerviano Medical Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-10
- **Primary completion:** 2009-09
- **Final completion:** 2010-09
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Low recruitment rate
- **Last updated:** 2014-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00872300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00872300, "PHA-739358 for the Treatment of Multiple Myeloma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00872300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*